Microcalcification is one of the most reliable clinical features of the malignancy risk of breast cancer, and it is associated with enhanced tumour aggressiveness and poor prognosis. However, its underlying molecular mechanism remains unclear.
Clinical data were retrieved to analyse the association between calcification and bone metastasis in patients with breast cancer. Using multiple human breast cancer cell lines, the osteogenic cocktail model was established in vitro to demonstrate calcification-exacerbated metastasis. Migration and invasion characteristics were determined by wound healing and transwell migration. mRNA and protein expression were identified by quantitative PCR and western blotting. Metabolic alterations in breast cancer cells were evaluated using Seahorse Analyser.
The osteogenic differentiation of human breast cancer cells activated the classical TGF-β/Smad signalling pathway and the non-canonical MAPK pathway, which, in turn, exacerbated the progression of epithelial–mesenchymal transition (EMT). The metabolic programme switched to enhancing mitochondrial oxidative phosphorylation (OXPHOS) upon osteogenic differentiation. Rotenone was used to inhibit the OXPHOS complex during osteogenesis to block mitochondrial function, consequently reversing the EMT phenotype.
This study provides important insights into the mechanisms involved in breast cancer bone metastasis, and outlines a possible strategy to intervene in OXPHOS for the treatment of breast tumours.
Subscribe to Journal
Get full journal access for 1 year
only $20.79 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fitzmaurice, C., Abate, D., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdel-Rahman, O. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 5, 1749–1768 (2019).
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
O’Grady, S. & Morgan, M. P. Microcalcifications in breast cancer: from pathophysiology to diagnosis and prognosis. Biochim. Biophys. Acta Rev. Cancer 1869, 310–320 (2018).
Bundred, S. M., Zhou, J., Whiteside, S., Morris, J., Wilson, M., Hurley, E. et al. Impact of full-field digital mammography on pre-operative diagnosis and surgical treatment of mammographic microcalcification. Breast Cancer Res. Treat. 143, 359–366 (2014).
Dang, D., Prasad, H. & Rao, R. Secretory pathway Ca(2+) -ATPases promote in vitro microcalcifications in breast cancer cells. Mol. Carcinog. 56, 2474–2485 (2017).
Azimi, I., Roberts-Thomson, S. J. & Monteith, G. R. Calcium influx pathways in breast cancer: opportunities for pharmacological intervention. Br. J. Pharm. 171, 945–960 (2014).
Futakuchi, M., Fukamachi, K. & Suzui, M. Heterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. Adv. Drug Deliv. Rev. 99, 206–211 (2016).
Bussard, K. M., Gay, C. V. & Mastro, A. M. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 27, 41–55 (2008).
Li, X. Q., Du, X., Li, D. M., Kong, P. Z., Sun, Y., Liu, P. F. et al. ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFbeta signaling pathway. Cancer Res. 75, 3302–3313 (2015).
Shupp, A. B., Kolb, A. D., Mukhopadhyay, D. & Bussard, K. M. Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers 10, 182 (2018).
Roato, I. & Ferracini, R. Cancer stem cells, bone and tumor microenvironment: key players in bone metastases. Cancers 10, 56 (2018).
Romero-Moreno, R., Curtis, K. J., Coughlin, T. R., Cristina Miranda-Vergara, M., Dutta, S., Natarajan, A. et al. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat. Commun. 10, 4404 (2019).
Kaiser, T., Teufel, I., Geiger, K., Vater, Y., Aicher, W. K., Klein, G. et al. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells. Breast Cancer Res. Treat. 140, 35–48 (2013).
Jin, H., Pi, J., Huang, X., Huang, F., Shao, W., Li, S. et al. BMP2 promotes migration and invasion of breast cancer cells via cytoskeletal reorganization and adhesion decrease: an AFM investigation. Appl. Microbiol. Biotechnol. 93, 1715–1723 (2012).
Li, X. Q., Lu, J. T., Tan, C. C., Wang, Q. S. & Feng, Y. M. RUNX2 promotes breast cancer bone metastasis by increasing integrin alpha5-mediated colonization. Cancer Lett. 380, 78–86 (2016).
Chakraborty, G., Jain, S. & Kundu, G. C. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68, 152–161 (2008).
Wang, L., Song, L., Li, J., Wang, Y., Yang, C., Kou, X. et al. Bone sialoprotein-alphavbeta3 integrin axis promotes breast cancer metastasis to the bone. Cancer Sci. 110, 3157–3172 (2019).
Pang, X., Gong, K., Zhang, X., Wu, S., Cui, Y. & Qian, B. Z. Osteopontin as a multifaceted driver of bone metastasis and drug resistance. Pharm. Res. 144, 235–244 (2019).
Kovacheva, M., Zepp, M., Schraad, M., Berger, S. & Berger, M. R. Conditional knockdown of osteopontin inhibits breast cancer skeletal metastasis. Int. J. Mol. Sci. 20, 4918 (2019).
Moulder, D. E., Hatoum, D., Tay, E., Lin, Y. & McGowan, E. M. The roles of p53 in mitochondrial dynamics and cancer metabolism: the pendulum between survival and death in breast cancer? Cancers 10, 189 (2018).
Putignani, L., Raffa, S., Pescosolido, R., Aimati, L., Signore, F., Torrisi, M. R. et al. Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Res. Treat. 110, 439–452 (2008).
Zhou, T., Zhang, B., Wei, P., Du, Y., Zhou, H., Yu, M. et al. Energy metabolism analysis reveals the mechanism of inhibition of breast cancer cell metastasis by PEG-modified graphene oxide nanosheets. Biomaterials 35, 9833–9843 (2014).
Witkiewicz, A. K., Whitaker-Menezes, D., Dasgupta, A., Philp, N. J., Lin, Z., Gandara, R. et al. Using the “reverse Warburg effect” to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 11, 1108–1117 (2012).
Pacheco-Velazquez, S. C., Robledo-Cadena, D. X., Hernandez-Resendiz, I., Gallardo-Perez, J. C., Moreno-Sanchez, R. & Rodriguez-Enriquez, S. Energy metabolism drugs block triple negative breast metastatic cancer cell phenotype. Mol. Pharm. 15, 2151–2164 (2018).
Wang, Y. Y., Attane, C., Milhas, D., Dirat, B., Dauvillier, S., Guerard, A. et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight 2, e87489 (2017).
Li, S., Lu, J., Chen, Y., Xiong, N., Li, L., Zhang, J. et al. MCP-1-induced ERK/GSK-3beta/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells. Cell Mol. Immunol. 14, 621–630 (2017).
Bae, S., Lee, M. J., Mun, S. H., Giannopoulou, E. G., Yong-Gonzalez, V., Cross, J. R. et al. MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRalpha. J. Clin. Investig. 127, 2555–2568 (2017).
Raja, R., Kale, S., Thorat, D., Soundararajan, G., Lohite, K., Mane, A. et al. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1alpha-mediated VEGF-dependent angiogenesis. Oncogene 33, 2053–2064 (2014).
Gui, T., Sun, Y., Shimokado, A. & Muragaki, Y. The roles of mitogen-activated protein kinase pathways in TGF-beta-induced epithelial-mesenchymal transition. J. Signal Transduct. 2012, 289243 (2012).
Demer, L. L. & Tintut, Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb. Vasc. Biol. 34, 715–723 (2014).
Wang, X., Chao, L., Chen, L., Tian, B., Ma, G., Zang, Y. et al. Correlation of mammographic calcifications with Her-2/neu overexpression in primary breast carcinomas. J. Digit Imaging 21, 170–176 (2008).
Seo, B. K., Pisano, E. D., Kuzimak, C. M., Koomen, M., Pavic, D., Lee, Y. et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad. Radiol. 13, 1211–1218 (2006).
Wan, X. C., Liu, C. P., Li, M., Hong, D., Li, D. M., Chen, H. X. et al. Staphylococcal enterotoxin C injection in combination with ascorbic acid promotes the differentiation of bone marrow-derived mesenchymal stem cells into osteoblasts in vitro. Biochem. Biophys. Res. Commun. 373, 488–492 (2008).
Cox, R. F., Hernandez-Santana, A., Ramdass, S., McMahon, G., Harmey, J. H. & Morgan, M. P. Microcalcifications in breast cancer: novel insights into the molecular mechanism and functional consequence of mammary mineralisation. Br. J. Cancer 106, 525–537 (2012).
Morgan, M. P., Cooke, M. M., Christopherson, P. A., Westfall, P. R. & McCarthy, G. M. Calcium hydroxyapatite promotes mitogenesis and matrix metalloproteinase expression in human breast cancer cell lines. Mol. Carcinog. 32, 111–117 (2001).
Rizwan, A., Paidi, S. K., Zheng, C., Cheng, M., Barman, I. & Glunde, K. Mapping the genetic basis of breast microcalcifications and their role in metastasis. Sci. Rep. 8, 1–10 (2018).
Woolf, D. K., Padhani, A. R. & Makris, A. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Ann. Oncol. 26, 1048–1057 (2015).
Queiroga, F. L., Raposo, T., Carvalho, M. I., Prada, J. & Pires, I. Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo 25, 455–465 (2011).
Reis, J., Oliveira, T., Pereira, A., Infante, P., Leal, N. & Faisca, P. Microtomographic characterization of calcifications in canine mammary tumours. Vet. Comp. Oncol. 18, 281–291 (2020).
Berridge, M. J., Bootman, M. D. & Roderick, H. L. Calcium signalling: dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 4, 517–529 (2003).
Kang, H., Kim, H., Lee, S., Youn, H. & Youn, B. Role of metabolic reprogramming in epithelial-mesenchymal transition (EMT). Int. J. Mol. Sci. 20, 2042 (2019).
Sciacovelli, M. & Frezza, C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J. 284, 3132–3144 (2017).
Gillies, R. J., Robey, I. & Gatenby, R. A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49, 24s–42s (2008).
Siu, M. K. Y., Jiang, Y. X., Wang, J. J., Leung, T. H. Y., Han, C. Y., Tsang, B. K. et al. Hexokinase 2 regulates ovarian cancer cell migration, invasion and stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 signaling cascades. Cancers 11, 813 (2019).
Patra, K. C., Wang, Q., Bhaskar, P. T., Miller, L., Wang, Z. B., Wheaton, W. et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24, 213–228 (2013).
Palmieri, D., Fitzgerald, D., Shreeve, S. M., Hua, E., Bronder, J. L., Weil, R. J. et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol. Cancer Res. 7, 1438–1445 (2009).
Chen, G. H., Zhang, Y. D., Liang, J. F., Li, W. Q., Zhu, Y., Zhang, M. et al. Deregulation of hexokinase ii is associated with glycolysis, autophagy, and the epithelial-mesenchymal transition in tongue squamous cell carcinoma under hypoxia. BioMed. Res. Int. 2018, 8480762 (2018).
Zheng, J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review). Oncol. Lett. 4, 1151–1157 (2012).
Zacksenhaus, E., Shrestha, M., Liu, J. C., Vorobieva, I., Chung, P. E. D., Ju, Y. J. et al. Mitochondrial OXPHOS induced by RB1 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis. Trends Cancer 3, 768–779 (2017).
LeBleu, V. S., O’Connell, J. T., Herrera, K. N. G., Wikman, H., Pantel, K., Haigis, M. C. et al. PGC-l alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 992–1003 (2014).
Signorile, A., De Rasmo, D., Cormio, A., Musicco, C., Rossi, R., Fortarezza, F. et al. Human ovarian cancer tissue exhibits increase of mitochondrial biogenesis and cristae remodeling. Cancers 11, 1350 (2019).
Lunetti, P., Di Giacomo, M., Vergara, D., De Domenico, S., Maffia, M., Zara, V. et al. Metabolic reprogramming in breast cancer results in distinct mitochondrial bioenergetics between luminal and basal subtypes. Febs J. 286, 688–709 (2019).
Jia, D., Park, J. H., Jung, K. H., Levine, H. & Kaipparettu, B. A. Elucidating the metabolic plasticity of cancer: mitochondrial reprogramming and hybrid metabolic states. Cells 7, 21 (2018).
Williams, G. S., Boyman, L., Chikando, A. C., Khairallah, R. J. & Lederer, W. J. Mitochondrial calcium uptake. Proc. Natl Acad. Sci. USA 110, 10479–10486 (2013).
Wu, Y., Xu, X., Ma, L., Yi, Q., Sun, W. & Tang, L. Calreticulin regulates TGF-beta1-induced epithelial mesenchymal transition through modulating Smad signaling and calcium signaling. Int. J. Biochem. Cell Biol. 90, 103–113 (2017).
Olea-Flores, M., Zuniga-Eulogio, M. D., Mendoza-Catalan, M. A., Rodriguez-Ruiz, H. A., Castaneda-Saucedo, E., Ortuno-Pineda, C. et al. Extracellular-signal regulated kinase: a central molecule driving epithelial-mesenchymal transition in cancer. Int. J. Mol. Sci. 20, 2885 (2019).
Liu, N. N., Xi, Y., Callaghan, M. U., Fribley, A., Moore-Smith, L., Zimmerman, J. W. et al. SMAD4 is a potential prognostic marker in human breast carcinomas. Tumour Biol. 35, 641–650 (2014).
Imamichi, Y., Waidmann, O., Hein, R., Eleftheriou, P., Giehl, K. & Menke, A. TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Biol. Chem. 386, 225–236 (2005).
Zhang, Y. E. Non-Smad signaling pathways of the TGF-beta family. Cold Spring Harb. Perspect. Biol. 9, a022129 (2017).
We thank all the members of the laboratory for their help in discussions and for providing technical assistance.
Ethics approval and consent to participate
This study was reviewed and approved by the ethics committee of Nanfang Hospital, Southern Medical University. Informed consent was obtained from all participants (reference number: NFEC-201706-K3-01). The study was conducted in accordance with the Declaration of Helsinki.
Consent to publish
All data generated or analysed during this study are included in this paper.
The authors declare no competing interests.
This research was supported by the National Key Research and Development Program of China (grant numbers “2019YFC0117301” and “2019YFC0121903”), Natural Science Foundation of Guangdong Province (grant number “2019A1515011168”) and Medical Research Fund of Guangdong Province (grant number “A2017496”).
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hu, Y., Xu, W., Zeng, H. et al. OXPHOS-dependent metabolic reprogramming prompts metastatic potential of breast cancer cells under osteogenic differentiation. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-01040-y